7 completed. 7 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 2 | Completed 2 |
Follow Heart Failure With Reduced Ejection Fraction: new trials by email Literature Review of Heart Failure With Reduced Ejection Fraction trials Research Report on Heart Failure With Reduced Ejection Fraction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Heart Failure With Reduced Ejection Fraction Polypill Implementation Strategy in Sri Lanka HFrEF Polypill, Comparator Arm - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Washington University School of Medicine | 40 | 2025-02-15 | 2025-05-08 |
| A Study to Assess the Effect of Danicamtiv on the Drug Levels of Midazolam in Participants With Stable Heart Failure Danicamtiv, Midazolam - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Bristol-Myers Squibb | 13 | 2023-08-17 | 2024-04-04 |
| Ketone Pharmacokinetic Study in HFrEF DeltaG (250 mg/kg), DeltaG (500 mg/kg) - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Duke University | 20 | 2023-06-02 | 2024-12-27 |
| Phase Ib/IIa Trial With AC01 in Patients With HFrEF AC01, Placebo Minitablets - Heart Failure With Reduced Ejection Fraction | Phase 1 / Phase 2 | Completed | AnaCardio AB | 58 | 2023-02-23 | 2026-05-07 |
| Study of JK07 in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) JK07, Matching Placebo - Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Salubris Biotherapeutics Inc | 14 | 2020-09-21 | 2025-07-09 |
| Thiamine Supplementation in Heart Failure: a Pilot Randomized Controlled Crossover Trial Thiamine, Placebo - Heart Failure, Heart Failure With Reduced Ejection Fraction | Phase 1 | Completed | Hamilton Health Sciences Corporation | 24 | 2018-04-02 | 2021-08-31 |
| v4 Study Evaluating the Safety, Tolerability and Preliminary Pharmacokinetics and Pharmacodynamics of MYK-491 MYK-491, Placebo - Heart Failure With Reduced Ejection Fraction, Dilated Cardiomyopathy | Phase 1 / Phase 2 | Completed | Bristol-Myers Squibb | 52 | 2018-02-06 | 2023-02-02 |
Heart Failure (3) · Cardiomyopathy, Dilated (1) · Fibromatosis, Gingival, 2 (1) · Ketosis (1) · Thiamine Deficiency (1)
Cardiovascular Diseases (4) · Heart Diseases (4) · Nutritional and Metabolic Diseases (2) · Acid-Base Imbalance (1) · Acidosis (1) · Avitaminosis (1) · Cardiomegaly (1) · Cardiomyopathies (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Deficiency Diseases (1) · Genetic Diseases, Inborn (1) · Laminopathies (1) · Malnutrition (1) · Metabolic Diseases (1) · Nutrition Disorders (1)
Bristol-Myers Squibb (2) · AnaCardio AB (1) · Duke University (1) · Hamilton Health Sciences Corporation (1) · Salubris Biotherapeutics Inc (1) · Washington University School of Medicine (1)
United States (4) · Netherlands (2) · Sweden (2) · United Kingdom (2) · Canada (1) · France (1) · Germany (1) · Italy (1) · Poland (1) · Sri Lanka (1)
Eric KC Wong, MD FRCPC (1) · Lars H Lund, MD PhD (1) · Senthil Selvaraj, MD, MSTR, MA (1) · Wilson Tang, MD (1)
PMID 30258648, PMID 40139871, PMID 40664424, PMID 40737710, PMID 42341796
K23HL161348 (1)